Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.623250
0.00340.56%
At Close: -
$0.657000
0.035.42%
After Hours: Sep 17, 6:28 PM EDT
15 minutes delayed
Comments
Loading...
BioLine Rx (NASDAQ:BLRX) Stock, Analyst Ratings, Price Targets, Forecasts
BioLine Rx Ltd has a consensus price target of $9 based on the ratings of 3 analysts. The high is $21 issued by HC Wainwright & Co. on June 3, 2024. The low is $2 issued by Jones Trading on September 4, 2024. The 3 most-recent analyst ratings were released by Jones Trading, HC Wainwright & Co., and HC Wainwright & Co. on September 4, 2024, June 3, 2024, and May 29, 2024, respectively. With an average price target of $14.67 between Jones Trading, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 2132.37% upside for BioLine Rx Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jones Trading
HC Wainwright & Co.
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for BioLine Rx
Data brought to you by Benzinga APIs
FAQ
What is the target price for BioLine Rx (BLRX) stock?
The latest price target for BioLine Rx (NASDAQ:BLRX) was reported by Jones Trading on September 4, 2024. The analyst firm set a price target for $2.00 expecting BLRX to rise to within 12 months (a possible 204.41% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioLine Rx (BLRX)?
The latest analyst rating for BioLine Rx (NASDAQ:BLRX) was provided by Jones Trading, and BioLine Rx initiated their buy rating.
When was the last upgrade for BioLine Rx (BLRX)?
There is no last upgrade for BioLine Rx
When was the last downgrade for BioLine Rx (BLRX)?
There is no last downgrade for BioLine Rx.
When is the next analyst rating going to be posted or updated for BioLine Rx (BLRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioLine Rx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioLine Rx was filed on September 4, 2024 so you should expect the next rating to be made available sometime around September 4, 2025.
Is the Analyst Rating BioLine Rx (BLRX) correct?
While ratings are subjective and will change, the latest BioLine Rx (BLRX) rating was a initiated with a price target of $0.00 to $2.00. The current price BioLine Rx (BLRX) is trading at is $0.66, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.